Cannabis at a Crossroads: Capital Crunches and the Schedule III Pivot

BOSTON, MA – October 21, 2026 — For an industry born out of counterculture and propelled by a speculative gold rush, the legal cannabis sector is now facing the ultimate test of permanence: the ruthless, unyielding mechanics of the capital markets. The days of easy money and euphoric valuations have receded, leaving behind a landscape where operational efficiency, defensive balance sheet management, and regulatory agility are the only true markers of a winner.

This stark reality serves as the backdrop for Blank Rome LLP’s 10th Annual State of the Cannabis Industry Conference, set to convene on October 26 at the Omni Boston Hotel at the Seaport. The gathering of prominent executives, regulators, and financial heavyweights arrives at a consequential inflection point. Operators are simultaneously bracing for the historic, albeit complex, federal rescheduling of cannabis to Schedule III, while navigating a severe capital crunch that is forcing widespread consolidation and distressed asset sales.

"Reaching the 10th anniversary of the State of the Cannabis Industry Conference is an important milestone for our firm and for the community that has helped make this event one of the industry’s leading national forums," said Frank A. Segall, partner and co-chair of Blank Rome’s Boston office and Cannabis practice. "The cannabis market has changed dramatically since we launched the conference, but the value of bringing together the people driving that change has remained constant. This year’s program honors the pioneers who helped build the modern industry while creating space for candid conversations about the regulatory, financial, and operational decisions that will shape its future."

The Capital Crunch and the Distressed M&A Wave

To commemorate a decade of industry evolution, the conference will introduce its inaugural Cannabis Industry Hall of Fame. The first class of inductees features a trio of multi-state operator (MSO) titans: Boris Jordan, co-founder and CEO of Curaleaf; George Archos, CEO of Verano; and Charlie Bachtell, CEO of Cresco Labs. These executives shepherded their respective enterprises through the chaotic early days of state-by-state legalization, building national footprints in a fragmented legal environment.

Yet, as these pioneers gather to reflect on the past, the present demands a ruthless focus on survival. The industry is currently gripped by a wave of distressed mergers and acquisitions, driven by prolonged federal inaction and a punishing cost of capital. Many companies that secured debt during more optimistic market cycles are now facing looming maturities with few favorable refinancing options.

"The industry is at a consequential point, as businesses confront capital constraints, consolidation, regulatory uncertainty, and an increasingly competitive marketplace," noted Scott H. Moskol, partner and co-chair of Blank Rome’s Cannabis practice. "These conditions are prompting companies, investors, and lenders to reassess strategies, manage risk, identify opportunities, and explore new paths to sustainable growth."

With traditional banking avenues largely closed off, cannabis operators have historically relied on specialty finance firms and regional lenders. Representatives from active industry financiers—including Needham Bank, Altmore Capital, Chicago Atlantic, and East West Bank—will be present to dissect the current lending environment. For many undercapitalized operators, the inability to secure affordable refinancing is forcing a binary choice: insolvency or acquisition. This dynamic is rapidly accelerating consolidation, allowing well-capitalized MSOs to acquire distressed assets at steep discounts, fundamentally reshaping the competitive hierarchy.

The Schedule III Pivot: Salvation or New Red Tape?

Perhaps the most anticipated shift in the sector's history is the administrative move to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act. For years, businesses have been suffocated by Section 280E of the IRS tax code, which prevents entities trafficking in Schedule I or II substances from deducting ordinary business expenses. This punitive measure has routinely resulted in effective tax rates exceeding 70 percent, draining cash flow and stifling reinvestment.

Rescheduling to Schedule III effectively neutralizes the 280E burden, a development that promises to instantly repair the cash flow profiles of viable operators. However, as legal experts and compliance officers are quick to point out, Schedule III is not a panacea, nor is it equivalent to full federal legalization.

The transition introduces a formidable new layer of federal oversight. Cannabis businesses will be subjected to Drug Enforcement Administration (DEA) registration requirements. This mandates adherence to stringent federal standards for security, recordkeeping, distribution, and reporting—a jarring transition for operators accustomed solely to state-level compliance. The upcoming panel, "From State Regulation to Federal Rescheduling," will critically examine this tension. Industry analysts warn that while the tax relief is a monumental victory, the compliance costs and operational friction associated with DEA oversight could disproportionately impact smaller businesses, further fueling the consolidation trend dominated by the larger MSOs.

Navigating the Patchwork: State Realities vs. Federal Stagnation

While the federal government inches toward rescheduling, comprehensive legislative reform remains elusive. The SAFER Banking Act, designed to provide a safe harbor for financial institutions serving state-legal cannabis businesses, continues to languish in Congress. This legislative stagnation ensures that the industry remains heavily reliant on cash, creating persistent security vulnerabilities and operational bottlenecks.

In the absence of federal banking access, operators are turning to innovative financial technology. Emerging payment, point-of-sale, and data-analytics solutions are attempting to bridge the gap, helping businesses manage cash flow, improve transparency, and satisfy the rigorous reporting demands of the Financial Crimes Enforcement Network (FinCEN).

Simultaneously, the burden of day-to-day governance remains squarely on the shoulders of state regulators. Mature markets are grappling with their own growing pains, including market saturation, illicit competition, and the complex implementation of social equity programs. This dynamic will take center stage during a fireside chat with Christopher Harding, the recently appointed Chair of the Massachusetts Cannabis Control Commission (CCC).

Harding assumed leadership during a critical transition period for the CCC, tasked with moving the agency past previous operational dysfunctions and toward a more stable, efficient regulatory posture. His mandate—to transform the commission into a predictable, highly functional administrative body—mirrors the broader maturation of the industry itself. For cannabis operators, the era of explosive, unchecked growth has definitively ended. In its place is a demanding new paradigm where long-term permanence requires navigating a labyrinth of state enforcement, bracing for federal pharmaceutical-grade compliance, and executing flawless balance sheet defense in a capital-starved environment.